CTSS and myeloid sarcoma: Despite years of interest in therapeutically targeting cysteine cathepsins in MS, and sporadic autoimmune clinical trials of lead compounds that inhibit cathepsin S [27], EAE has not been attempted in mice genetically deficient in individual cysteine cathepsins.